The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.
Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapies approaches.
The virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients.
Join us and leading experts from Roche, CytomX, Philogen, Bristol-Myers Squibb, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose, determining the mechanisms of action and hear the latest data coming out of the clinic.
If you are a research team striving to advance your cytokine therapies, this is the best suited online networking forum which has been curated for you.
Access the official agenda for more information.
The post Cytokine-Based Cancer Immunotherapies Summit appeared first on .
